Published in Biol Chem on April 27, 2011
Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol (2012) 1.12
Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res (2012) 0.84
Examining acute and chronic effects of short- and long-chain fatty acids on peptide YY (PYY) gene expression, cellular storage and secretion in STC-1 cells. Eur J Nutr (2012) 0.78
The significance of the nuclear farnesoid X receptor (FXR) in β cell function. Islets (2012) 0.78
Bile acids and bariatric surgery. Mol Aspects Med (2017) 0.75
Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men. Eur J Nutr (2016) 0.75
In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1). Sci Pharm (2011) 0.75
Metagenomic and functional analysis of hindgut microbiota of a wood-feeding higher termite. Nature (2007) 7.42
NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal (2006) 2.95
Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res (2003) 2.50
Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol (2011) 2.44
NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A (2010) 2.36
Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension (2002) 2.20
Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J (2006) 1.90
Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: Evidence for tissue specificity of leptin resistance. Eur Heart J (2006) 1.81
Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension (2008) 1.68
Strain-dependent variation in vascular responses to nitric oxide in the isolated murine heart. J Mol Cell Cardiol (2002) 1.49
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol (2009) 1.41
Protection against endotoxemia-induced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I. FASEB J (2005) 1.38
GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys (2008) 1.38
Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res (2010) 1.35
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther (2009) 1.29
Essential role of troponin I in the positive inotropic response to isoprenaline in mouse hearts contracting auxotonically. J Physiol (2004) 1.09
Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. Anal Chem (2013) 1.08
Oxidative stress in heart failure. More than just damage. Eur Heart J (2003) 1.08
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci (2008) 1.06
Conformational change of mitochondrial complex I increases ROS sensitivity during ischemia. Antioxid Redox Signal (2013) 0.98
Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Eur J Pharmacol (2009) 0.92
Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential. Eur J Nutr (2014) 0.90
NADPH oxidase and heart failure. Curr Opin Pharmacol (2006) 0.90
Acute and chronic effects of dietary fatty acids on cholecystokinin expression, storage and secretion in enteroendocrine STC-1 cells. Mol Nutr Food Res (2010) 0.89
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol (2007) 0.88
Inward rectifier potassium channels in the HL-1 cardiomyocyte-derived cell line. J Cell Physiol (2010) 0.87
The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling. Br J Pharmacol (2012) 0.85
Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol (2015) 0.85
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. Eur J Endocrinol (2009) 0.84
Vascular endothelial function and blood pressure homeostasis in mice overexpressing IGF binding protein-1. Diabetes (2003) 0.83
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biol Chem (2005) 0.81
Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol Chem (2004) 0.81
Surgical optimization and characterization of a minimally invasive aortic banding procedure to induce cardiac hypertrophy in mice. Exp Physiol (2012) 0.81
GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J Med Chem (2006) 0.81
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. Expert Opin Investig Drugs (2010) 0.81
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol (2014) 0.80
Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice. Peptides (2005) 0.80
Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells. Endocr Res (2004) 0.79
Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes. Biol Chem (2007) 0.79
Metabolic and structural properties of human obestatin {1-23} and two fragment peptides. Peptides (2010) 0.79
Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. Exp Gerontol (2005) 0.79
Examining acute and chronic effects of short- and long-chain fatty acids on peptide YY (PYY) gene expression, cellular storage and secretion in STC-1 cells. Eur J Nutr (2012) 0.78
Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. Am J Physiol Endocrinol Metab (2007) 0.78
Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16). Regul Pept (2006) 0.78
Grape-seed procyanidins modulate cellular membrane potential and nutrient-induced GLP-1 secretion in STC-1 cells. Am J Physiol Cell Physiol (2013) 0.77
Long-term beneficial effects of vanadate, tungstate, and molybdate on insulin secretion and function of cultured beta cells. Pancreas (2004) 0.77
A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J Pharmacol Exp Ther (2005) 0.77
Cooperative enhancement of insulinotropic action of GLP-1 by acetylcholine uncovers paradoxical inhibitory effect of beta cell muscarinic receptor activation on adenylate cyclase activity. Biochem Pharmacol (2003) 0.77
Adult cardiac fibroblast proliferation is modulated by calcium/calmodulin-dependent protein kinase II in normal and hypertrophied hearts. Pflugers Arch (2013) 0.76
Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J Med Chem (2005) 0.76
Hormone profiling in a novel enteroendocrine cell line pGIP/neo: STC-1. Metabolism (2012) 0.76
Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem Pharmacol (2006) 0.76
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. Diabetes Metab Res Rev (2007) 0.76
N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression. Cell Biol Int (2004) 0.76
Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. Biol Chem (2007) 0.76
In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1). Sci Pharm (2011) 0.75
Deleterious effects of supplementation with dehydroepiandrosterone sulphate or dexamethasone on rat insulin-secreting cells under in vitro culture condition. Biosci Rep (2006) 0.75
Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. Arch Biochem Biophys (2007) 0.75